Clinical trials: Prevention & Control
Episodic Cluster Headache
A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Episodic Cluster Headache (ECH)
This is a 13-week, multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study to compare the efficacy and safety of 2 dose regimens of TEV-48125 (Fremanezumab) versus placebo in adult…
- Trial name
- NCT02945046
- Testing
- Fremanezumab
- Where
- 82 sites in United States, Australia and 10 more
- Volunteers
- 169 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Chemotherapy-induced Nausea and Vomiting
Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029)
The purpose of this study was to determine the appropriate dosing regimen of fosaprepitant, when administered with ondansetron (with or without dexamethasone), for the prevention of CINV in children from birth to <17 years of…
- Trial name
- NCT01697579
- Testing
- Fosaprepitant, Ondansetron, 5-hydroxytryptamine 3 antagonist
- Volunteers
- 240 people
- Sponsor
- Merck Sharp & Dohme LLC
COVID-19
AZD7442 - a Potential Combination Therapy for the Prevention and Treatment of COVID-19
In this first-in-humans dose escalation study, AZD7442 (AZD8895 + AZD1061) will be evaluated for safety, tolerability, pharmacokinetics, and generation of anti-drug antibodies (ADAs).
- Trial name
- NCT04507256
- Testing
- AZD7442
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Migraine
Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine
The study is being conducted to evaluate two doses of TEV-48125 in adult patients with chronic migraine
- Trial name
- NCT02621931
- Testing
- Fremanezumab
- Where
- 273 sites in United States, Canada and 7 more
- Volunteers
- 1,130 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Migraine
A Study of Rizatriptan for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis
This study will provide additional efficacy data for rizatriptan when used for an acute migraine attack in patients already taking topiramate for migraine prophylaxis.
- Trial name
- NCT00812006
- Testing
- rizatriptan benzoate
- Volunteers
- 108 people
- Sponsor
- Organon and Co
Pressure Incidence Prevention
Pressure Injury Prevention in the ICU With Multi-Layer Foam Dressings
A Multi-Centre, Open, Non-controlled, Clinical Investigation to Evaluate the User Friendliness and Wear Time of Multi-layer Foam Dressings With Safetac® for Pressure Injury Prevention in the Intensive Care Unit
- Trial name
- PUP16_01 (NCT02962882)
- Testing
- Mepilex Border
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Molnlycke Health Care AB
HPV Infections
Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041)
A study to test the safety and effectiveness of Quadrivalent HPV (types 6, 11, 16, 18) L1 VLP vaccine against combined incidence of HPV 6/11/16/18-related persistent infection and vaccine type-specific genital disease among…
- Trial name
- NCT00834106
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
- Volunteers
- 3,006 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Migraine
A Study of LY2951742 (Galcanezumab) in Japanese Participants With Episodic Migraine
The main purpose of this study is to determine the efficacy of the study drug Galcanezumab in Japanese participants with episodic migraine.
- Trial name
- NCT02959177
- Testing
- Galcanezumab
- Where
- 47 sites in Japan
- Volunteers
- 459 people
- Sponsor
- Eli Lilly and Company
Angioedema
A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
The main aim of this study is to check if repeated subcutaneous (SC) injections of lanadelumab can prevent angioedema attacks in teenagers and adults with non-histaminergic angioedema with normal C1-INH.
- Trial name
- NCT04206605
- Testing
- Lanadelumab
- Where
- 45 sites in United States, Canada and 8 more
- Volunteers
- 77 people
- Sponsor
- Takeda
Chronic Migraine
Assessment of LBR-101 In Chronic Migraine
The purpose of the study is to determine whether monthly subcutaneous administration of LBR-101 (fremanezumab) is safe and provides migraine prevention in patients with chronic migraine.
- Trial name
- NCT02021773
- Testing
- LBR-101 High Dose, LBR-101 Low Dose
- Where
- 57 sites in United States
- Volunteers
- 264 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Postoperative Nausea and Vomiting
Study of APD421 as PONV Treatment (Prior Prophylaxis)
Double-blind, randomised, parallel-group, placebo-controlled, adaptive, seamless, dose-selecting study to compare the efficacy of APD421 to placebo as treatment of established PONV, in patients who have had prior PONV prophylaxis.
- Trial name
- NCT02646566
- Testing
- APD421
- Where
- 8 sites in United States, France and 1 more
- Volunteers
- 705 people
- Sponsor
- Acacia Pharma Ltd
Migraine
Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine
The study is being conducted to evaluate two doses of TEV-48125 in adult patients with episodic migraine
- Trial name
- NCT02629861
- Testing
- Fremanezumab
- Where
- 275 sites in United States, Canada and 7 more
- Volunteers
- 875 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Depressive Disorder, Treatment-Resistant
A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression
The purpose of this study is to assess the efficacy of intranasal esketamine plus an oral antidepressant compared with an oral antidepressant (active comparator) plus intranasal placebo in delaying relapse of depressive symptoms…
- Trial name
- SUSTAIN-1 (NCT02493868)
- Testing
- Esketamine, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant)
- Where
- 155 sites in United States, Belgium and 13 more
- Volunteers
- 719 people
- Sponsor
- Janssen Research & Development, LLC
Migraine
A Study Designed to Test the Effectiveness and Safety of Treating Patients With Lacosamide for Migraine Prophylaxis
The purpose of this study is to see how safe and effective Lacosamide (LCM) is when taken by mouth, twice a day for up to 18 weeks to prevent migraines.
- Trial name
- SP906 (NCT00440518)
- Testing
- Lacosamide
- Where
- 24 sites in United States
- Volunteers
- 218 people
- Sponsor
- UCB Pharma
Scar Prevention, Scar Reduction
A Study to Evaluate the Safety and Efficacy of AZX100 Drug Product Following Excision of Keloid Scars
The purpose of this study was to determine the safety of AZX100 Drug Product and to determine whether it was effective in preventing or reducing re-growth of surgically removed keloid scars.
- Trial name
- NCT00825916
- Testing
- AZX100 Drug Product
- Where
- 2 sites in United States
- Volunteers
- 59 people
- Sponsor
- Capstone Therapeutics
Influenza Prevention
A Clinical Study to Evaluate an Experimental Universal Influenza Vaccine, INFLUENZA G1 mHA, in Healthy Adults
The primary purpose of this study is to evaluate safety/ reactogenicity of INFLUENZA G1 mini-hemagglutinin stem-derived protein vaccine antigen (mHA), with or without Al(OH)3 adjuvant, in healthy adults greater than or equal to…
- Trial name
- NCT05901636
- Testing
- INFLUENZA G1 mHA, Al(OH)3
- Where
- 4 sites in United States
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Alzheimer Disease, Alzheimer Disease (AD)
Phase I Clinical Study of AV-1959R: Abeta-targeting Anti-Alzheimer's Vaccine
This Phase 1 clinical trial evaluates the safety, tolerability, and immune response of the adjuvanted AV-1959R vaccine in healthy adults aged 40-60.
- Conditions
- Alzheimer Disease, Alzheimer Disease (AD), Alzheimers Disease Prevention
- Trial name
- NCT06831812
- Testing
- AV-1959R (Abeta vaccine)
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Nuravax, Inc.
Ototoxicity
SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity
The primary objective of this study is to determine the safety and efficacy of SPI-1005 treatment in CF patients with active pulmonary exacerbation that are receiving an IV course of tobramycin, determined by comparing hearing…
- Trial name
- NCT02819856
- Testing
- SPI-1005 Ebselen 200mg Capsule x1, SPI-1005 Ebselen 200mg Capsule x2, SPI-1005 Ebselen 200mg Capsule x3
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Sound Pharmaceuticals, Incorporated
Chemotherapy-Induced Nausea and Vomiting
An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting
NETU-08-18 is a two-arm clinical study assessing efficacy and safety of a single oral dose of netupitant and palonosetron, two antiemetic drugs, versus oral palonosetron, both given with oral dexamethasone.
- Trial name
- NCT01339260
- Testing
- Netupitant and Palonosetron, Palonosetron, Dexamethasone
- Where
- 172 sites in United States, Argentina and 13 more
- Volunteers
- 1,455 people
- Sponsor
- Helsinn Healthcare SA
Influenza
A Prospective Study to Evaluate the Safety of a New Trivalent Intranasal Influenza Vaccine
This prospective annual release study was designed to assess the safety of a trivalent influenza virus vaccine using a new strain recommended for the 2008-2009 influenza season not previously contained in the trivalent intranasal…
- Trial name
- MI-MA182 (NCT00677820)
- Testing
- Trivalent influenza virus vaccine
- Where
- 3 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC